Sandbox:tables
Jump to navigation
Jump to search
Classification
Clinical definition | Pathophysiology | ||||
---|---|---|---|---|---|
BP fall | Time line for symptoms after standing | Symptoms | Resolving | ||
Initial orthostatic hypotension (iOH) |
|
|
|
|
|
Neurogenic orthostatic hypotension (nOH) |
|
|
|
| |
Delayed orthostatic hypotension (dOH) |
|
|
|
| |
Neurally mediated syncope (vOH) |
|
|
|
| |
Cardiovascular orthostatic hypotension (cOH) |
Non-Pharmacological methods | Mechanism of alleviating hypotension | Recommendations |
---|---|---|
Elastic stockings |
|
|
Physical Maneuvers |
|
|
Head up tilt sleeping |
|
|
Intravascular volume |
|
|
Intake of cold water |
|
|
Drop of systolic BP > 20 mmHg (30 for hypertensive patients) | |||||||||||||||||||||||||||||||||||||||||||||||||
Symptomatic | Asymptomatic | ||||||||||||||||||||||||||||||||||||||||||||||||
Non-pharmacological treatment | Observation and follow-up | ||||||||||||||||||||||||||||||||||||||||||||||||
Persistance of symtoms | |||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacological Treatment | |||||||||||||||||||||||||||||||||||||||||||||||||
No supine hypertension or chronic heart failure | Supine hypertension or chronic heart failure: | ||||||||||||||||||||||||||||||||||||||||||||||||
Fludrocortisone Midodrine | Midodrine | ||||||||||||||||||||||||||||||||||||||||||||||||
Stepwise approach
Steps to approach a patient | |||||||||||||||||||||||||||||||||||
When we should suspect orthostatic hypotension? Unexplained fall/syncope Typical symptoms Patient history Current pharmacological treatment | |||||||||||||||||||||||||||||||||||
Initial assessment (outpatient clinic. ED and hospital): Physical examination Laboratory assessment | |||||||||||||||||||||||||||||||||||
Initial Therapy
- Preferred regimen (1): Fludrocortisone acetate at a dose of 0.1 mg per day, administered in the morning, which can eventually be increased up to 0.3 mg per day.
- Considered first-line regimen for hypotension in the absence of heart failure and supine hypertension
- Preferred regimen (2): Midodrine 2.5 to 10 mg three times a day.
- Max dose should not exceed 40 mg/day.
- Preferred regimen (2): Droxidopa starts at 100 mg and escalates to 600 mg three times per day.
- Patients should not take droxidopa within four to five hours of bedtime in order to limit supine hypertension.
Secondline Therapy
- Preferred regimen (1): Erythropoietin is administered SC or IV at doses between 25 to 75 units/kg three times a week.
- Preferred regimen (1): Methylxanthine caffeine 100 to 250 mg three times a day with meals.
- Preferred regimen (1): Pyridostigmine initiated at a dose of 30 mg three times daily, up to a maximum dose of 90 mg three times daily.
- Preferred regimen (1): Nonsteroidal anti-inflammatory drugs are rarely effective as monotherapy
- They can supplement treatment with fludrocortisone or a sympathomimetic agent.
Thirdline Therpay
- Preferred regimen (1): Atomoxetine
- Preferred regimen (1): Vasopressin analogs (desmopressin (DDAVP))
- Preferred regimen (1): Yohimbine a single dose of yohimbine (5.4 mg).
- Yohimbine has limited availability in the United States.
- Preferred regimen (1): Somatostatin subcutaneous doses range from 25 to 200 mcg.
- Preferred regimen (1): Ergotamine-caffeine (1 mg/100 mg) up to twice-daily dosing in patients with orthostatic hypotension.
- Preferred regimen (1): Metoclopramide and domperidone